Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for Carson Gray�
-0.38 (-1.62%)
Real-time:   2:08PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 22.40 - 23.18
52 week 12.50 - 26.89
Open 22.90
Vol / Avg. 237,732.00/497,508.00
Mkt cap 678.48M
P/E     -
Div/yield     -
EPS -3.45
Shares 28.91M
Beta 2.44
Inst. own 72%
May 4, 2015
Q1 2015 Dynavax Technologies Corp Earnings Release (Estimated) Add to calendar
Mar 5, 2015
Q4 2014 Dynavax Technologies Corp Earnings Release
Mar 2, 2015
Dynavax Technologies Corp at Cowen Health Care Conference - Webcast
Feb 24, 2015
Dynavax Technologies Corp at RBC Healthcare Conference
Jan 15, 2015
Dynavax Technologies Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -978.74% -822.35%
Operating margin -984.32% -827.69%
EBITD margin - -814.97%
Return on average assets -62.69% -52.91%
Return on average equity -80.51% -63.27%
Employees 197 -
CDP Score - -


2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company�s pipeline of product candidates includes HEPLISAV, its autoimmune program partnered with GlaxoSmithKline (GSK), its therapy for asthma partnered with AstraZeneca AB (AstraZeneca), and clinical-stage programs for its Universal Flu vaccine and hepatitis B therapy. As of December 31, 2011, its intellectual property portfolio included 18 issued United States patents, claiming compositions and formulations of immunostimulatory sequences (ISS) and immunoregulatory sequence (IRS), their methods of use or processes for their manufacture.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 52
Bio & Compensation  - Reuters
David L. Johnson Chief Accounting Officer, Vice President
Age: 60
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 56
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 65
Bio & Compensation  - Reuters
Francis R. Cano Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters